Kunachowicz Dominika, Tomecka Paulina, Sędzik Mikołaj, Kalinin Jarosław, Kuźnicki Jacek, Rembiałkowska Nina
Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.
Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Cells. 2025 Jul 10;14(14):1057. doi: 10.3390/cells14141057.
Hypoxia, characterized by a reduction in tissue oxygen levels, is a hallmark of many solid tumors and affects a range of cellular processes, including DNA repair. In low-oxygen conditions, cancer cells often suppress key DNA repair pathways such as homologous recombination (HR), leading to the accumulation of DNA damage and increased genomic instability. These changes not only drive tumor progression but also contribute to resistance against conventional therapies. Hypoxia significantly reduces the effectiveness of oxygen-dependent treatments, including radiotherapy and many chemotherapeutic agents. To address this limitation, bioreductive drugs have been developed that become selectively activated in hypoxic environments, providing targeted cytotoxic effects within oxygen-deprived tumor regions. Additionally, the rapid growth of tumors often results in disorganized and inefficient vasculature, further impairing the delivery of oxygen and therapeutic agents. This review explores the molecular mechanisms by which hypoxia disrupts DNA repair and contributes to treatment resistance. It also presents emerging therapeutic strategies aimed at targeting the hypoxic tumor microenvironment to improve treatment efficacy and patient outcomes.
缺氧以组织氧水平降低为特征,是许多实体瘤的标志,影响一系列细胞过程,包括DNA修复。在低氧条件下,癌细胞通常会抑制关键的DNA修复途径,如同源重组(HR),导致DNA损伤的积累和基因组不稳定性增加。这些变化不仅推动肿瘤进展,还导致对传统疗法产生抗性。缺氧显著降低了包括放疗和许多化疗药物在内的氧依赖性治疗的有效性。为了解决这一局限性,已开发出生物还原药物,这些药物在缺氧环境中被选择性激活,在缺氧的肿瘤区域提供靶向细胞毒性作用。此外,肿瘤的快速生长常常导致血管系统紊乱和效率低下,进一步损害氧气和治疗药物的输送。本综述探讨了缺氧破坏DNA修复并导致治疗抗性的分子机制。它还介绍了旨在靶向缺氧肿瘤微环境以提高治疗效果和患者预后的新兴治疗策略。